https://modelmedicines.com/ https://modelmedicines.com/newsroom https://modelmedicines.com/publications https://modelmedicines.com/pipeline https://modelmedicines.com/aidd-code https://modelmedicines.com/privacy https://modelmedicines.com/contact https://modelmedicines.com/investors https://modelmedicines.com/science https://modelmedicines.com/careers https://modelmedicines.com/about https://modelmedicines.com/404 https://modelmedicines.com/newsroom/model-medicines-to-present-ultra-large-virtual-screening-and-agentic-ai-breakthroughs-at-ai-convergence-small-molecule-discovery-summit https://modelmedicines.com/newsroom/model-medicines%E2%80%99-amesnettm-achieves-best-in-class-performance-in-ai-driven-ames-mutagenicity-prediction https://modelmedicines.com/newsroom/model-medicines-to-highlight-two-ind-track-assets-record-setting-ai-platform-at-bio-investment-growth-summit-2026 https://modelmedicines.com/newsroom/model-medicines-to-present-data-on-two-drug-candidates-at-biocom-global-partnering-conference-2026 https://modelmedicines.com/newsroom/model-medicines-to-present-evidence-of-first-direct-acting-antiviral-potent-against-hcv-hbv-hdv-and-co-infections-at-croi-2026 https://modelmedicines.com/newsroom/model-medicines-demonstrates-first-single-agent-antiviral-active-against-both-hepatitis-c-and-hepatitis-b https://modelmedicines.com/newsroom/hepdart-2025 https://modelmedicines.com/newsroom/model-medicines-unveils-groundbreaking-preclinical-data-oral-mdl-001-demonstrates-superiority-or-equivalence-to-three-standard-of-care-antivirals-nirmatrelvir-remdesivir-and-sofosbuvir-across-respiratory-and-hepatic-viral-diseases https://modelmedicines.com/newsroom/mdl-001-as-a-next-generation-hcv-thumb-1-inhibitor-with-clinical-stage-safety https://modelmedicines.com/newsroom/record-scale-ai-screening-with-model-medicines-on-google-cloud-galileo-achieves-325-billion-molecule-throughput-for-oncology-drug-discovery https://modelmedicines.com/newsroom/model-medicines-325-billion-molecule-throughput-oncology-screen-google-cloud-cancer-ai-symposium https://modelmedicines.com/newsroom/model-medicines-to-present-preclinical-data-readout-for-mdl-001-a-direct-acting-broad-spectrum-antiviral-targeting-a-novel-viral-mechanism-at-idweek-2025 https://modelmedicines.com/newsroom/selected-to-present-at-barda-enabling-technologies-showcase https://modelmedicines.com/newsroom/coronaviruses-from-the-common-cold-to-a-common-occurrence https://modelmedicines.com/newsroom/the-foundations-of-broad-spectrum https://modelmedicines.com/newsroom/model-medicines-to-present-preclinical-proof-of-concept-data-for-broad-spectrum-antiviral-mdl-001-at-id-week-2025 https://modelmedicines.com/newsroom/model-medicines-selected-for-barda-vanguard-building-the-future-of-u-s-health-security https://modelmedicines.com/newsroom/model-medicines-named-to-fierce-15 https://modelmedicines.com/newsroom/selected-for-barda-vanguard-program-strengthening-u-s-national-defense-against-biological-threats https://modelmedicines.com/newsroom/model-medicines-advances-ai-driven-drug-safety-prediction-with-amesnet-achieving-unprecedented-accuracy-and-sensitivity-in-mutagenicity-testing https://modelmedicines.com/newsroom/model-medicines-featured-on-bloomberg-s-vanguards-of-health-care-transforming-drug-discovery-with-ai https://modelmedicines.com/newsroom/model-medicines-ceo-daniel-haders-ii-to-speak-at-bloomberg-s-4th-annual-generative-ai-conference https://modelmedicines.com/newsroom/amesnet-a-deep-learning-model-enhancing-generalization-in-ames-mutagenicity-prediction https://modelmedicines.com/newsroom/antivirals-from-one-too-many-to-one-to-many https://modelmedicines.com/newsroom/biotech-s-undead-zombies-and-vampires https://modelmedicines.com/newsroom/transforming-pandemic-preparedness-ai-driven-predictive-tools-and-next-generation-broad-spectrum-antivirals https://modelmedicines.com/newsroom/the-future-of-drug-discovery-2025-as-the-inflection-year-for-hybrid-ai-and-quantum-computing https://modelmedicines.com/newsroom/the-stat-news-report-a-wake-up-call-for-ai-drug-discovery https://modelmedicines.com/newsroom/model-medicines-gains-industry-recognition-for-ai-driven-antiviral-breakthroughs https://modelmedicines.com/newsroom/model-medicines-unveils-generative-ai-multi-modal-therapeutic-pipeline-breakthrough-demonstrating-end-to-end-drug-discovery-capabilities https://modelmedicines.com/newsroom/model-medicines-named-among-top-ai-drug-development-startups-to-watch-in-2025 https://modelmedicines.com/newsroom/demonstrating-end-to-end-drug-discovery-galileo-unlocks-generative-ai-for-chemistry https://modelmedicines.com/newsroom/model-medicines-icahn-school-of-medicine-at-mount-sinai-and-university-of-california-san-diego-researchers-publish-groundbreaking-preprint-on-mdl-001-a-broad-spectrum-antiviral https://modelmedicines.com/newsroom/mdl001-oral-safe-well-tolerated-broad-spectrum-inhibitor-viral-polymerases https://modelmedicines.com/newsroom/cphi https://modelmedicines.com/newsroom/genengnews-ten-companies-to-watch-in-ai-drug-discovery https://modelmedicines.com/newsroom/ai-hit-rate https://modelmedicines.com/newsroom/nomination-of-preclinical-candidate-mdl-4101 https://modelmedicines.com/newsroom/dr-launa-aspeslet https://modelmedicines.com/newsroom/the-aidd-code https://modelmedicines.com/newsroom/tsx-investor-event https://modelmedicines.com/newsroom/two-new-preprint-papers https://modelmedicines.com/newsroom/model-medicines-reveals-breakthrough-ai-discovery-rdrp-thumb-1-a-universal-rna-antiviral-target-and-mdl-001-a-potent-inhibitor https://modelmedicines.com/newsroom/model-medicines-publishes-groundbreaking-preprint-on-ai-driven-drug-discovery https://modelmedicines.com/newsroom/maximizing-your-business-potential https://modelmedicines.com/newsroom/20th-biopharma-drug-discovery-nexus-conference https://modelmedicines.com/newsroom/dissimilar-drug-like-novel-chemical-entities-(ddl-nces)-using-multimodal-generative-ai https://modelmedicines.com/newsroom/biochemistry-s-hidden-matrix-atomic-constellations https://modelmedicines.com/newsroom/barda-industry-day https://modelmedicines.com/newsroom/jpm-cbrn-medical-techwatch https://modelmedicines.com/newsroom/precision-in-drug-discovery-preclinical-summit-2023 https://modelmedicines.com/newsroom/vanity-metrics-black-boxes-therapeutics https://modelmedicines.com/newsroom/barda-techwatch-meeting https://modelmedicines.com/newsroom/breaking-the-data-dogma https://modelmedicines.com/newsroom/tiecon-2023 https://modelmedicines.com/newsroom/download-day https://modelmedicines.com/newsroom/overcoming-pains https://modelmedicines.com/newsroom/cryo-em https://modelmedicines.com/newsroom/the-tripledemic-infographic-whitepaper https://modelmedicines.com/newsroom/5th-annual-evercore-isi-healthconx-conference https://modelmedicines.com/newsroom/2022-bmo-healthcare-conference https://modelmedicines.com/newsroom/model-medicines-announces-launch-of-oncology-programs-with-multiple-ai-discovered-compounds-demonstrating-drug-like-activity-for-two-high-value-difficult-to-drug-oncogenic-and-epigenetic-targets https://modelmedicines.com/newsroom/cen-next-generation-covid-19-antivirals https://modelmedicines.com/newsroom/model-medicines-accepted-to-join-the-alliance-for-artificial-intelligence-in-healthcare-(aaih) https://modelmedicines.com/newsroom/model-medicines-covid-19-drug-development-program-highlighted-by-catalyst-health-2-0 https://modelmedicines.com/newsroom/model-medicines-highlighted-as-vc-backed-startup-battling-covid-19-by-medcitynews https://modelmedicines.com/newsroom/model-medicines-covid-19-drug-development-program-highlighted-by-freshbrewedtech https://modelmedicines.com/newsroom/model-medicines-joins-the-fight-to-battle-the-global-covid-19-pandemic https://modelmedicines.com/newsroom/model-medicines-discuss-ai-drug-discovery-at-jpm-2020-healthcare-week